Embla Medical hf

Analysts Lift Embla Medical hf Price Target on Stronger Growth and Improved Margins

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

09 Feb 25

Updated

05 Dec 25

Views

38

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-2.3%

7D

0.9%

Loading

1Y

-2.3%

7D

0.9%

You can edit this narrative until Dec 6 4:25 AM. Then, changes will post as Updates.

Author's Valuation

DKK 37.49.9% undervalued

AnalystConsensusTarget Fair Value

Shared on 05 Dec 25

EMBLA: Share Buyback And Ukraine Mobility Initiative Will Support Steady Outlook

Analysts have modestly raised their price target on Embla Medical hf., reflecting slightly lower perceived risk, a marginal uptick in long term profit margins, and a small increase in the expected future earnings multiple, while keeping their overall fair value estimate broadly unchanged at approximately $37.40 per share. What's in the News Opened a new prosthetic clinic in Kyiv as part of the three year "Iceland Supports Mobility in Ukraine" initiative, which targets high quality prosthetic care and rehabilitation for up to 1,000 Ukrainian amputees (Key Developments) Announced that the Ukraine initiative, co financed with the Government of Iceland and implemented with charity partner Future for Ukraine (FFU), has a total estimated value of USD 11 million over three years (Key Developments) Reiterated full year 2025 guidance for 5 to 6% organic sales growth, indicating confidence in near term demand and execution (Key Developments) Completed a share buyback tranche totaling 1,449,010 shares, or about 0.34% of shares outstanding, for USD 7 million under the program announced on February 7, 2025 (Key Developments) Valuation Changes Fair Value Estimate remained unchanged at approximately $37.40 per share, indicating no material shift in the overall valuation outcome.

Shared on 20 Nov 25

EMBLA: Share Buyback And Kyiv Clinic Launch Will Support Bullish Outlook

Analysts have maintained their target price for Embla Medical hf. at €37.40, citing minor adjustments to discount rates and future market assumptions, but no significant change in company fundamentals.

Shared on 05 Nov 25

EMBLA: Stable Outlook Will Reflect Earnings Guidance and Recent Share Buyback Completion

Analysts have maintained their price target for Embla Medical hf. at €37.40.

Shared on 22 Oct 25

Fair value Increased 4.91%

Analysts have raised their price target for Embla Medical hf. from $35.65 to $37.40, citing improved revenue growth and higher profit margin forecasts.

Shared on 19 Sep 25

Fair value Increased 4.24%

The consensus Analyst Price Target for Embla Medical hf has risen to DKK35.65, primarily reflecting a substantial increase in the future P/E ratio while net profit margin remains stable. What's in the News Completed repurchase of 923,277 shares (0.22%) for $4.3 million under previously announced buyback.

Shared on 01 May 25

Fair value Increased 6.94%

Shared on 23 Apr 25

Fair value Decreased 8.81%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 1.21%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 6.70%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 3.40%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Decreased 2.72%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 1.10%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Increased 9.18%

AnalystConsensusTarget has increased profit margin from 9.7% to 10.7% and increased shares outstanding growth rate from -0.0% to 0.0%.

AnalystConsensusTarget Fair Value

DKK 37.4

9.9% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

8.58%

Medical Equipment revenue growth rate

6.79%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.38%

Calculation

US$125.23m

Earnings '28

x

24.80x

PE Ratio '28

=

US$3.11b

Market Cap '28

US$3.11b

Market Cap '28

/

430.61m

No. shares '28

=

US$7.21

Share Price '28

US$7.21 Share Price '28

Discounted to 2025 @ 7.36% p.a.

=

US$5.83

Fair Value '25

US$5.83 Fair Value '25

Converted to DKK @ 6.4064 USD/DKK Exchange Rate

=

DKK 37.35

Fair Value '25